ClinicalTrials.gg
CompletedNCT04887064Updated Apr 19, 2024Results posted

Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

A Phase 1 interventional study of Sotorasib in Hepatic Impairment, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The main purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in participants with moderate or severe hepatic impairment compared to participants with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic Impairment
  • Sotorasib
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria

All Participants

  • Participant has provided before initiation of any study-specific activities/procedures
  • Participants between 18 and 70 years of age
  • between 18 and 38 kg/m\^2
  • Females of nonchildbearing potential defined as permanently sterile or

Participants with Normal Hepatic Function

  • In good health, determined by no findings from medical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory evaluations

Participants with Hepatic Impairment

  • B or C classification with clinical laboratory values and clinical examination findings
  • Documented medical history of chronic liver disease

Key Exclusion Criteria

All Participants

  • Female participants with a positive pregnancy test at Screening or Check-in
  • Male participants with a pregnant partner or partner planning to become pregnant who are unwilling to practice abstinence or use a condom for 7 days after dosing
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance
  • Participant has received a dose of an drug (new chemical entity) within the past 30 days or 5 half-lives, whichever is longer, prior to Check-in
  • Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer)
  • All herbal medicines vitamins, and supplements consumed by the subject within the 30 days prior to enrollment
  • Alcohol consumption from 48 hours prior to Check-in
  • Positive test for illicit drugs, cotinine (tobacco or nicotine use), and/or alcohol use at Check-in
  • Positive test at Screening

Participants with Normal Hepatic Function

  • Positive or panel at Screening. Subjects whose results are compatible with prior immunity (vaccination or prior infection) may be included
  • (ALT) or aspartate aminotransferase (AST) > (ULN) at Screening or Check-in
  • Total levels > ULN at Screening or Check-in
  • A corrected for heart rate based on the Fridericia correction (QTcF) interval > 450 msec in male subjects or > 470 msec in female subjects or history/evidence of long QT syndrome at Screening or Check-in, confirmed by calculating the mean of the original value and 2 repeats

Participants with Hepatic Impairment

  • Values outside the normal range for liver function tests that are not consistent with their hepatic condition, as determined by the Investigator (or designee)
  • A QTcF interval > 470 msec in male subjects or > 480 msec in female subjects at Screening or Check-in, confirmed by calculating the mean of the original value and 2 repeats
  • Use of a new medication, or a change in dose, for the treatment, or worsening of, hepatic encephalopathy within 30 days prior to Check-in
  • Presence of a portosystemic shunt
  • Evidence of severe ascites
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Normal Hepatic Function

    Drug: Sotorasib

  • Experimental
    Moderate Hepatic Impairment

    Drug: Sotorasib

  • Experimental
    Severe Hepatic Impairment

    Drug: Sotorasib

Interventions

  • Sotorasib will be administered as an oral tablet.

    Also known as: AMG 510

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1

  2. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1

  3. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1

Secondary outcomes

  1. Number of Participants Who Experienced One or More Treatment Emergent Adverse Events (TEAEs)

    TEAEs were defined as any adverse events (AEs) that started during or after dosing, or started prior to dosing and increased in severity after dosing. Any clinically significant changes in clinical laboratory evaluations, 12-lead electrocardiograms (ECGs) and vital signs were also reported as TEAEs.

    Time frame: Day 1 to Day 8

  2. Unbound Cmax (Cmax,u) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1

  3. Unbound AUClast (AUClast,u) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1

  4. Unbound AUCinf (AUCinf,u) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1

  5. Unbound Apparent Total Plasma Clearance (CLu/F) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1

  6. Unbound Apparent Volume of Distribution During the Terminal Phase (Vz,u/F) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1

07

Results

Posted Apr 19, 2024

Participant flow

Participants were enrolled at research centers in the United States from April 2021 to March 2022.

Participant flow — Overall Study
MilestoneNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Started785
Completed785
Not completed000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Sotorasib
ng/mLNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Maximum Observed Plasma Concentration (Cmax) of Sotorasib5080 ± 108.54850 ± 60.67250 ± 15.7
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
h*ng/mLNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib28700 ± 87.821500 ± 58.229900 ± 12.6
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib
h*ng/mLNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib29000 ± 86.421700 ± 58.230100 ± 12.2
SecondaryNumber of Participants Who Experienced One or More Treatment Emergent Adverse Events (TEAEs)

TEAEs were defined as any adverse events (AEs) that started during or after dosing, or started prior to dosing and increased in severity after dosing. Any clinically significant changes in clinical laboratory evaluations, 12-lead electrocardiograms (ECGs) and vital signs were also reported as TEAEs.

Time frame:
Day 1 to Day 8
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment Emergent Adverse Events (TEAEs)
ParticipantsNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Number of Participants Who Experienced One or More Treatment Emergent Adverse Events (TEAEs)121
SecondaryUnbound Cmax (Cmax,u) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Reported as:
Geometric mean · ng/mL
Unbound Cmax (Cmax,u) of Sotorasib
ng/mLNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Unbound Cmax (Cmax,u) of Sotorasib183 ± 240.8400 ± 110.91220 ± 9.8
SecondaryUnbound AUClast (AUClast,u) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Reported as:
Geometric mean · h*ng/mL
Unbound AUClast (AUClast,u) of Sotorasib
h*ng/mLNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Unbound AUClast (AUClast,u) of Sotorasib694 ± 146.31320 ± 71.04680 ± 29.4
SecondaryUnbound AUCinf (AUCinf,u) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Reported as:
Geometric mean · h*ng/mL
Unbound AUCinf (AUCinf,u) of Sotorasib
h*ng/mLNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Unbound AUCinf (AUCinf,u) of Sotorasib742 ± 156.71340 ± 69.64680 ± 29.4
SecondaryUnbound Apparent Total Plasma Clearance (CLu/F) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Reported as:
Geometric mean · L/h
Unbound Apparent Total Plasma Clearance (CLu/F) of Sotorasib
L/hNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Unbound Apparent Total Plasma Clearance (CLu/F) of Sotorasib1290 ± 156.7715 ± 69.6205 ± 29.4
SecondaryUnbound Apparent Volume of Distribution During the Terminal Phase (Vz,u/F) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Reported as:
Geometric mean · liters
Unbound Apparent Volume of Distribution During the Terminal Phase (Vz,u/F) of Sotorasib
litersNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Unbound Apparent Volume of Distribution During the Terminal Phase (Vz,u/F) of Sotorasib7080 ± 275.63820 ± 115.2928 ± 39.1

Adverse events

Collected over Day 1 to Day 8. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Hepatic Function0/7 (0%)0/7 (0%)1/7 (14.3%)
Moderate Hepatic Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Severe Hepatic Impairment0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent other events
Most frequent other events
EventNormal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic Impairment
Electrocardiogram qt prolongedInvestigations0/70/81/5
RashSkin and subcutaneous tissue disorders0/70/81/5
ConstipationGastrointestinal disorders1/70/80/5
Abdominal distensionGastrointestinal disorders0/71/80/5
DiarrhoeaGastrointestinal disorders0/71/80/5
Dry mouthGastrointestinal disorders0/71/80/5
NauseaGastrointestinal disorders0/71/80/5
ContusionInjury, poisoning and procedural complications0/71/80/5
Sensory disturbanceNervous system disorders0/71/80/5

Baseline characteristics

Safety Population: All participants who received sotorasib and had at least 1 postdose safety assessment.

Age, Continuous
Age, Continuous(years)Normal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Mean59.0 ± 7.3558.5 ± 5.6651.6 ± 7.3757.0 ± 7.10
Sex: Female, Male
Sex: Female, Male(Participants)Normal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Female3429
Male44311
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Normal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Hispanic or Latino46313
Not Hispanic or Latino3227
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Normal Hepatic FunctionModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
White68418
Black or African American1012
08

Study locations

5 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Clinical Pharmacology Of Miami LLC
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • American Research Corporation
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research - San Antonio
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Mar 2022, 10 months.

Results were first posted in Apr 2024, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2021
First posted
May 14, 2021
StartActual
Apr 22, 2021
Primary completionActual
Mar 9, 2022
CompletionActual
Mar 9, 2022
Results first posted
Apr 19, 2024
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04887064
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 14, 2021
Start date
Apr 22, 2021
Primary completion
Mar 9, 2022
Completion
Mar 9, 2022
Results posted
Apr 19, 2024
Last update
Apr 19, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion